It is widely assumed that simply switching to once-daily therapy will improve adherence and outcome, but this has not been proven. Click here to read more about this interesting study.
There are some people with HIV who seem to be able to control the disease well without therapy. Understanding why this happens is key to designing therapeutic vaccines and other strategies that may boost the body's ability to control HIV. Read the latest study on non-progressors from Dr. Bruce Walker's lab.
It has become increasingly popular and important to switch therapy in patients with fully suppressed viral loads. Unfortunately, the studies are just coming in. Here's one retrospective review of 24 patients who were taking d4T (stavudine, Zerit), 3TC (lamivudine, Epivir), and a non-nucleoside and then switched the d4T for tenofovir (TDF, Viread). Dr. Andy Pavia reports.
Coverage Provided By:
The Infectious Diseases Society of America is an organization of physicians, scientists, and other health care professionals dedicated to the promotion and recognition of excellence in infectious disease research, patient care, public health, prevention and education. This year's conference featured discussions, interactive information sessions, slide presentations and other activities on topics ranging from tuberculosis to HIV resistance testing. Click here for extensive information on what this conference holds in store. Click here for a list of abstracts to be presented.
Funding for this coverage is provided, in part, by unrestricted educational grants from GlaxoSmithKline and Ortho Biotech. All coverage is © 2002 Body Health Resources Corporation.